Orexigen™ begins third trial in Phase III clinical trial program

Orexigen™ Therapeutics, Inc. announced on October 17, the start of the third of four trials in its Phase III clinical trial program for Contrave™, one of it's two promising weight loss drugs.

This clinical trial is a 58-week study designed to assess the safety, tolerability and efficacy of Contrave™ in otherwise healthy, nondiabetic, obese patients. The trial is designed to take place at approximately 40 centers nationwide and will include about 1650 patients.

The first Phase III clinical trial for Contrave™ started enrolling subjects in April and is scheduled to run for 56 weeks and will test weight loss potential either alone or combined with intense diet, exercise and behavior modification.

The second Phase III trial started enrolling subjects in May. It's also scheduled to run 56 weeks and will be testing obese subjects with Type II diabetes.

The fourth Phase III trial is scheduled to begin enrollment sometime during the fourth quarter of 2007.

For more information, please visit http://ir.orexigen.com/releasedetail.cfm?ReleaseID=269637

Technorati Tags: Contrave™ naltrexone Diet Pills Weight Loss Pillsbupropion